Relief Therapeutics: A Swiss Biopharmaceutical Company Targeting Rare and Specialty Diseases
Relief Therapeutics Holding SA is a commercial-stage, Swiss-based biopharmaceutical company dedicated to the development and commercialization of innovative treatments for rare and debilitating diseases with high unmet medical needs. Headquartered in Geneva, Switzerland, and listed on the SIX Swiss Exchange (RLF) and quoted on the OTCQB in the U.S. (RLFTF, RLFTY), the company focuses its efforts on advancing therapeutic solutions in its core areas of expertise: rare metabolic disorders, rare skin diseases, and rare lung diseases. Relief Therapeutics employs a multifaceted strategy that includes in-house development, strategic acquisitions, and partnerships to build a balanced portfolio of revenue-generating products and a robust pipeline of clinical-stage drug candidates.
Continue…
Corporate Mission and Strategy
The core mission of Relief Therapeutics is to provide "therapeutic relief" to patients suffering from serious diseases where few or no effective treatment options exist. The company's strategy is centered on identifying, developing, and bringing to market novel, often patent-protected products. A key aspect of their approach involves mitigating development risk by focusing on molecules with a history of clinical use or a strong scientific rationale. This includes drug repurposing and leveraging innovative drug delivery platform technologies to improve the efficacy, safety, and convenience of treatments. The company has grown significantly through strategic acquisitions, most notably the 2021 acquisition of APR Applied Pharma Research SA, which brought a portfolio of commercial products and two proprietary technology platforms.
Commercial Products and Technology Platforms
Relief Therapeutics has successfully brought several products to market, which provide a revenue stream to help fund its research and development activities.
1. PKU GOLIKE? Product Family:
* This is the company's flagship commercial offering for the dietary management of Phenylketonuria (PKU), a rare inherited metabolic disorder.
* What it is: PKU GOLIKE is a line of phenylalanine-free medical foods (amino acid mixes) for children and adults.
* Service and Technology: The key innovation behind this product is the proprietary, patent-protected Physiomimic? Technology. This technology coats the amino acids, allowing for a prolonged-release profile that mimics the physiological absorption of natural proteins. This has two main benefits: it masks the notoriously unpleasant taste and odor of free amino acids, improving patient compliance, and it promotes more efficient absorption and utilization by the body.
* Products Offered: The line includes granules in convenient packets (PKU GOLIKE Plus?) and medical food bars (PKU GOLIKE BAR?) that can be easily integrated into a patient's daily diet.
2. Legacy Commercial Products:
Through licensing and distribution partnerships, primarily via its subsidiary APR, Relief also commercializes a portfolio of established products in certain European markets. These include well-known brands such as Voltadol? (diclofenac) for pain relief and Setofilm? (ondansetron) for nausea and vomiting.
3. Proprietary Technology Platforms:
* Physiomimic? Technology: As used in the GOLIKE? line, this drug delivery system is designed to control the release and absorption of active ingredients.
* TEHCLO? Technology: A platform for developing highly pure, stabilized acid-oxidizing solutions, such as hypochlorous acid, for therapeutic use, particularly in dermatology.
Clinical Development Pipeline
Relief Therapeutics maintains a diversified pipeline of drug candidates aimed at addressing significant unmet needs in rare diseases.
1. RLF-OD032 (for Phenylketonuria - PKU):
* What it is: A novel, next-generation drug candidate for PKU. It is a ready-to-use, highly concentrated liquid formulation of sapropterin dihydrochloride.
* Service/Benefit: This product is being developed to address the limitations of current PKU treatments by offering improved convenience and portability, potentially enhancing treatment compliance and quality of life for both adult and pediatric patients.
2. RLF-TD011 (for Epidermolysis Bullosa - EB):
* What it is: An investigational drug product for Epidermolysis Bullosa, a group of rare and severe genetic disorders that cause the skin to be extremely fragile and blister easily.
* Technology: Developed using the company's proprietary TEHCLO? technology, RLF-TD011 is a hypotonic, acid-oxidizing solution containing hypochlorous acid.
* Service/Benefit: Delivered as a spray, it is designed to offer potent antimicrobial and anti-inflammatory activity, creating a wound environment conducive to healing while aiming to reduce the heavy burden of infection control and intensive wound care for EB patients. The U.S. FDA has granted this candidate Orphan Drug and Rare Pediatric Disease designations.
3. ACER-001 (OLPRUVA?) (for Urea Cycle Disorders - UCDs):
* What it is: A proprietary, taste-masked formulation of sodium phenylbutyrate. It is approved in the U.S. as OLPRUVA? for the treatment of certain Urea Cycle Disorders.
* Partnership/Service: Through a collaboration agreement with Acer Therapeutics (now a subsidiary of Zevra Therapeutics), Relief holds the exclusive development and commercialization rights for this product in Europe and is working to secure regulatory approval there.
4. RLF-100? (Aviptadil):
* What it is: RLF-100? is a synthetic form of Vasoactive Intestinal Peptide (VIP), a naturally occurring human peptide known to have potent anti-inflammatory, vasodilatory, and lung-protective properties.
* Pipeline Indications: Relief is developing proprietary intravenous and inhaled formulations of Aviptadil to treat severe respiratory conditions. While it gained significant attention for its investigation as a treatment for respiratory failure in COVID-19, the primary focus for its development now includes other rare pulmonary diseases such as pulmonary sarcoidosis and checkpoint inhibitor-induced pneumonitis (CIP). The FDA has granted RLF-100? Orphan Drug designation for the treatment of sarcoidosis.
